{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:19:14Z","timestamp":1793690354684,"version":"4.5.1"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,12,3]],"date-time":"2015-12-03T00:00:00Z","timestamp":1449100800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1038\/nrrheum.2015.164","type":"journal-article","created":{"date-parts":[[2015,12,3]],"date-time":"2015-12-03T05:45:30Z","timestamp":1449121530000},"page":"111-122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":104,"title":["Targeting of proangiogenic signalling pathways in chronic inflammation"],"prefix":"10.1038","volume":"12","author":[{"given":"Sander W.","family":"Tas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrissta X.","family":"Maracle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emese","family":"Balogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Szekanecz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,3]]},"reference":[{"key":"BFnrrheum2015164_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nm0195-27","volume":"1","author":"J Folkman","year":"1995","unstructured":"Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27\u201331 (1995).","journal-title":"Nat. Med."},{"key":"BFnrrheum2015164_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/BOR.0b013e328337c95a","volume":"22","author":"Z Szekanecz","year":"2011","unstructured":"Szekanecz, Z., Besenyei, T., Szentpetery, A. & Koch, A. E. Angiogenesis and vasculogenesis in rheumatoid arthritis. Curr. Opin. Rheumatol. 22, 299\u2013306 (2011).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum2015164_CR3","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/ncprheum0647","volume":"3","author":"Z Szekanecz","year":"2007","unstructured":"Szekanecz, Z. & Koch, A. E. Mechanisms of disease: angiogenesis in inflammatory diseases. Nat. Clin. Pract. Rheumatol. 3, 635\u2013643 (2007).","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"BFnrrheum2015164_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1083\/jcb.97.1.153","volume":"97","author":"JA Madri","year":"1983","unstructured":"Madri, J. A. & Williams, S. K. Capillary endothelial cell cultures: phenotypic modulation by matrix components. J. Cell. Biol. 97, 153\u2013165 (1983).","journal-title":"J. Cell. Biol."},{"key":"BFnrrheum2015164_CR5","doi-asserted-by":"publisher","unstructured":"Elshabrawy, H. A. et al. The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis http:\/\/dx.doi.org\/10.1007\/s10456-015-9477-2 .","DOI":"10.1007\/s10456-015-9477-2"},{"key":"BFnrrheum2015164_CR6","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.autrev.2011.04.020","volume":"10","author":"A Marrelli","year":"2011","unstructured":"Marrelli, A. et al. Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation? Autoimmun. Rev. 10, 595\u2013598 (2011).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum2015164_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000362276","volume":"51","author":"PC Stapor","year":"2014","unstructured":"Stapor, P. C., Sweat, R. S., Dashti, D. C., Betancourt, A. M. & Murfee, W. L. Pericyte dynamics during angiogenesis: new insights from new identities. J. Vasc. Res. 51, 163\u2013174 (2014).","journal-title":"J. Vasc. Res."},{"key":"BFnrrheum2015164_CR8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.V13225","volume":"1","author":"RS Cotran","year":"1990","unstructured":"Cotran, R. S. & Pober, J. S. Cytokine\u2013endothelial interactions in inflammation, immunity, and vascular injury. J. Am. Soc. Nephrol. 1, 225\u2013235 (1990).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrrheum2015164_CR9","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182\u20131186 (1971).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2015164_CR10","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1056\/NEJMra0910283","volume":"364","author":"HK Eltzschig","year":"2011","unstructured":"Eltzschig, H. K. & Carmeliet, P. Hypoxia and inflammation. N. Engl. J. Med. 364, 656\u2013665 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2015164_CR11","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1136\/ard.2009.119776","volume":"69","author":"CT Ng","year":"2010","unstructured":"Ng, C. T. et al. Synovial tissue hypoxia and inflammation in vivo. Ann. Rheum. Dis. 69, 1389\u20131395 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2015164_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/01.bor.0000155361.83990.5b","volume":"17","author":"PC Taylor","year":"2005","unstructured":"Taylor, P. C. & Sivakumar, B. Hypoxia and angiogenesis in rheumatoid arthritis. Curr. Opin. Rheumatol. 17, 293\u2013298 (2005).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum2015164_CR13","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.berh.2006.05.004","volume":"20","author":"DJ Veale","year":"2006","unstructured":"Veale, D. J. & Fearon, U. Inhibition of angiogenic pathways in rheumatoid arthritis: potential for therapeutic targeting. Best Pract. Res. Clin. Rheumatol. 20, 941\u2013947 (2006).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"BFnrrheum2015164_CR14","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.berh.2014.10.012","volume":"28","author":"CX Maracle","year":"2014","unstructured":"Maracle, C. X. & Tas, S. W. Inhibitors of angiogenesis: ready for prime time? Best Pract. Res. Clin. Rheumatol. 28, 637\u2013649 (2014).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"BFnrrheum2015164_CR15","doi-asserted-by":"publisher","first-page":"600","DOI":"10.4161\/mabs.21227","volume":"4","author":"P Kanakaraj","year":"2012","unstructured":"Kanakaraj, P. et al. Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs 4, 600\u2013613 (2012).","journal-title":"MAbs"},{"key":"BFnrrheum2015164_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1161\/01.RES.83.3.233","volume":"83","author":"T Asahara","year":"1998","unstructured":"Asahara, T. et al. Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. Circ. Res. 83, 233\u2013240 (1998).","journal-title":"Circ. Res."},{"key":"BFnrrheum2015164_CR17","doi-asserted-by":"publisher","first-page":"e8131","DOI":"10.1371\/journal.pone.0008131","volume":"4","author":"E Izquierdo","year":"2009","unstructured":"Izquierdo, E. et al. Immature blood vessels in rheumatoid synovium are selectively depleted in response to anti-TNF therapy. PLoS ONE 4, e8131 (2009).","journal-title":"PLoS ONE"},{"key":"BFnrrheum2015164_CR18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.2174\/157016110791112296","volume":"8","author":"MC Rico","year":"2009","unstructured":"Rico, M. C., Rough, J. J., Del Carpio-Cano, F. E., Kunapuli, S. P. & DeLa Cadena, R. A. The axis of thrombospondin-1, transforming growth factor \u03b2 and connective tissue growth factor: an emerging therapeutic target in rheumatoid arthritis. Curr. Vasc. Pharmacol. 8, 338\u2013343 (2009).","journal-title":"Curr. Vasc. Pharmacol."},{"key":"BFnrrheum2015164_CR19","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1126\/science.7512751","volume":"264","author":"PC Brooks","year":"1994","unstructured":"Brooks, P. C., Clark, R. A. & Cheresh, D. A. Requirement of vascular integrin \u03b1V\u03b23 for angiogenesis. Science 264, 569\u2013571 (1994).","journal-title":"Science"},{"key":"BFnrrheum2015164_CR20","doi-asserted-by":"publisher","first-page":"R112","DOI":"10.1186\/ar2318","volume":"9","author":"S Shahrara","year":"2007","unstructured":"Shahrara, S., Castro-Rueda, H. P., Haines, G. K. & Koch, A. E. Differential expression of the FAK family kinases in rheumatoid arthritis and osteoarthritis synovial tissues. Arthritis Res. Ther. 9, R112 (2007).","journal-title":"Arthritis Res. Ther."},{"issue":"Suppl. 2","key":"BFnrrheum2015164_CR21","doi-asserted-by":"publisher","first-page":"ii96","DOI":"10.1136\/ard.61.suppl_2.ii96","volume":"61","author":"RL Wilder","year":"2002","unstructured":"Wilder, R. L. Integrin \u03b1V\u03b23 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann. Rheum. Dis. 61 (Suppl. 2), ii96\u2013ii99 (2002).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2015164_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/jemt.10244","volume":"60","author":"Y Hiromatsu","year":"2003","unstructured":"Hiromatsu, Y. & Toda, S. Mast cells and angiogenesis. Microsc. Res. Tech 60, 64\u201369 (2003).","journal-title":"Microsc. Res. Tech"},{"key":"BFnrrheum2015164_CR23","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.4049\/jimmunol.1000556","volume":"185","author":"BJ Rabquer","year":"2010","unstructured":"Rabquer, B. J. et al. Junctional adhesion molecule-C is a soluble mediator of angiogenesis. J. Immunol. 185, 1777\u20131785 (2010).","journal-title":"J. Immunol."},{"key":"BFnrrheum2015164_CR24","first-page":"128","volume":"36","author":"SO Yoon","year":"2003","unstructured":"Yoon, S. O., Park, S. J., Yun, C. H. & Chung, A. S. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J. Biochem. Mol. Biol. 36, 128\u2013137 (2003).","journal-title":"J. Biochem. Mol. Biol."},{"key":"BFnrrheum2015164_CR25","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.2174\/138161206777947461","volume":"12","author":"R Benelli","year":"2006","unstructured":"Benelli, R., Lorusso, G., Albini, A. & Noonan, D. M. Cytokines and chemokines as regulators of angiogenesis in health and disease. Curr. Pharm. Des. 12, 3101\u20133115 (2006).","journal-title":"Curr. Pharm. Des."},{"key":"BFnrrheum2015164_CR26","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1128\/MCB.17.7.4015","volume":"17","author":"S Yoshida","year":"1997","unstructured":"Yoshida, S. et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor \u03b1-dependent angiogenesis. Mol. Cell. Biol. 17, 4015\u20134023 (1997).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrrheum2015164_CR27","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/329630a0","volume":"329","author":"SJ Leibovich","year":"1987","unstructured":"Leibovich, S. J. et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 329, 630\u2013632 (1987).","journal-title":"Nature"},{"key":"BFnrrheum2015164_CR28","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nri910","volume":"2","author":"Q Li","year":"2002","unstructured":"Li, Q. & Verma, I. M. NF-\u03baB regulation in the immune system. Nat. Rev. Immunol. 2, 725\u2013734 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"BFnrrheum2015164_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jneuroim.2005.09.018","volume":"171","author":"M Hangai","year":"2006","unstructured":"Hangai, M. et al. Sequential induction of angiogenic growth factors by TNF-\u03b1 in choroidal endothelial cells. J. Neuroimmunol. 171, 45\u201356 (2006).","journal-title":"J. Neuroimmunol."},{"key":"BFnrrheum2015164_CR30","doi-asserted-by":"publisher","first-page":"27348","DOI":"10.1074\/jbc.270.45.27348","volume":"270","author":"RM Strieter","year":"1995","unstructured":"Strieter, R. M. et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 270, 27348\u201327357 (1995).","journal-title":"J. Biol. Chem."},{"key":"BFnrrheum2015164_CR31","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/S0002-9440(10)65365-5","volume":"154","author":"R Salcedo","year":"1999","unstructured":"Salcedo, R. et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1\u03b1. Am. J. Pathol. 154, 1125\u20131135 (1999).","journal-title":"Am. J. Pathol."},{"key":"BFnrrheum2015164_CR32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.it.2007.05.007","volume":"28","author":"I Petit","year":"2007","unstructured":"Petit, I., Jin, D. & Rafii, S. The SDF-1\u2013CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol. 28, 299\u2013307 (2007).","journal-title":"Trends Immunol."},{"key":"BFnrrheum2015164_CR33","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1002\/art.37981","volume":"65","author":"T Isozaki","year":"2013","unstructured":"Isozaki, T. et al. Evidence that CXCL16 is a potent mediator of angiogenesis and is involved in endothelial progenitor cell chemotaxis: studies in mice with K\/B \u00d7 N serum-induced arthritis. Arthritis Rheum. 65, 1736\u20131746 (2013).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2015164_CR34","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3389\/fphys.2013.00159","volume":"4","author":"JL Owen","year":"2013","unstructured":"Owen, J. L. & Mohamadzadeh, M. Macrophages and chemokines as mediators of angiogenesis. Front. Physiol. 4, 159 (2013).","journal-title":"Front. Physiol."},{"key":"BFnrrheum2015164_CR35","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/path.4340","volume":"233","author":"J Deng","year":"2014","unstructured":"Deng, J. et al. IFN\u03b3-responsiveness of endothelial cells leads to efficient angiostasis in tumours involving down-regulation of Dll4. J. Pathol. 233, 170\u2013182 (2014).","journal-title":"J. Pathol."},{"key":"BFnrrheum2015164_CR36","first-page":"4095","volume":"63","author":"Z Qin","year":"2003","unstructured":"Qin, Z. et al. A critical requirement of interferon \u03b3-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res. 63, 4095\u20135100 (2003).","journal-title":"Cancer Res."},{"key":"BFnrrheum2015164_CR37","first-page":"44","volume":"1","author":"Z Szekanecz","year":"2009","unstructured":"Szekanecz, Z., Pakozdi, A., Szentpetery, A., Besenyei, T. & Koch, A. E. Chemokines and angiogenesis in rheumatoid arthritis. Front. Biosci. (Elite Ed.) 1, 44\u201351 (2009).","journal-title":"Front. Biosci. (Elite Ed.)"},{"key":"BFnrrheum2015164_CR38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/BOR.0b013e32805e87ae","volume":"19","author":"Z Szekanecz","year":"2007","unstructured":"Szekanecz, Z. & Koch, A. E. Macrophages and their products in rheumatoid arthritis. Curr. Opin. Rheumatol. 19, 289\u2013295 (2007).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum2015164_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2741\/s53","volume":"2","author":"Z Szekanecz","year":"2010","unstructured":"Szekanecz, Z., Vegvari, A., Szabo, Z. & Koch, A. E. Chemokines and chemokine receptors in arthritis. Front. Biosci. (Schol. Ed.) 2, 153\u2013167 (2010).","journal-title":"Front. Biosci. (Schol. Ed.)"},{"key":"BFnrrheum2015164_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1600-065X.2012.01111.x","volume":"246","author":"S Ghosh","year":"2012","unstructured":"Ghosh, S. & Hayden, M. S. Celebrating 25 years of NF-\u03baB research. Immunol. Rev. 246, 5\u201313 (2012).","journal-title":"Immunol. Rev."},{"key":"BFnrrheum2015164_CR41","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1126\/science.1062677","volume":"293","author":"U Senftleben","year":"2001","unstructured":"Senftleben, U. et al. Activation by IKK\u03b1 of a second, evolutionary conserved, NF-\u03baB signaling pathway. Science 293, 1495\u20131499 (2001).","journal-title":"Science"},{"key":"BFnrrheum2015164_CR42","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature04870","volume":"441","author":"M Karin","year":"2006","unstructured":"Karin, M. Nuclear factor-\u03baB in cancer development and progression. Nature 441, 431\u2013436 (2006).","journal-title":"Nature"},{"key":"BFnrrheum2015164_CR43","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/path.4403","volume":"234","author":"AR Noort","year":"2014","unstructured":"Noort, A. R. et al. NF-\u03baB-inducing kinase is a key regulator of inflammation-induced and tumour-associated angiogenesis. J. Pathol. 234, 375\u2013385 (2014).","journal-title":"J. Pathol."},{"key":"BFnrrheum2015164_CR44","doi-asserted-by":"publisher","first-page":"a011254","DOI":"10.1101\/cshperspect.a011254","volume":"4","author":"DK Morrison","year":"2012","unstructured":"Morrison, D. K. MAP kinase pathways. Cold Spring Harb. Perspect. Biol. 4 a011254 (2012).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"BFnrrheum2015164_CR45","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1038\/sj.onc.1210394","volume":"26","author":"MM McKay","year":"2007","unstructured":"McKay, M. M. & Morrison, D. K. Integrating signals from RTKs to ERK\/MAPK. Oncogene 26, 3113\u20133121 (2007).","journal-title":"Oncogene"},{"key":"BFnrrheum2015164_CR46","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/art.1780400520","volume":"40","author":"H Asahara","year":"1997","unstructured":"Asahara, H. et al. Direct evidence of high DNA binding activity of transcription factor AP-1 in rheumatoid arthritis synovium. Arthritis Rheum. 40, 912\u2013918 (1997).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2015164_CR47","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1002\/art.22705","volume":"56","author":"MA Amin","year":"2007","unstructured":"Amin, M. A. et al. Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Arthritis Rheum. 56, 1787\u20131797 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2015164_CR48","doi-asserted-by":"publisher","first-page":"28978","DOI":"10.1074\/jbc.274.41.28978","volume":"274","author":"P De Cesaris","year":"1999","unstructured":"De Cesaris, P. et al. Activation of Jun N-terminal kinase\/stress-activated protein kinase pathway by tumor necrosis factor \u03b1 leads to intercellular adhesion molecule-1 expression. J. Biol. Chem. 274, 28978\u201328982 (1999).","journal-title":"J. Biol. Chem."},{"key":"BFnrrheum2015164_CR49","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/eji.200838316","volume":"39","author":"F Scaldaferri","year":"2009","unstructured":"Scaldaferri, F. et al. The role of MAPK in governing lymphocyte adhesion to and migration across the microvasculature in inflammatory bowel disease. Eur. J. Immunol. 39, 290\u2013300 (2009).","journal-title":"Eur. J. Immunol."},{"key":"BFnrrheum2015164_CR50","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1053\/j.gastro.2012.11.005","volume":"144","author":"A Schirbel","year":"2013","unstructured":"Schirbel, A. et al. Pro-angiogenic activity of TLRs and NLRs: a novel link between gut microbiota and intestinal angiogenesis. Gastroenterology 144, 613\u2013623 e9 (2013).","journal-title":"Gastroenterology"},{"key":"BFnrrheum2015164_CR51","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s00109-001-0316-0","volume":"80","author":"N Wernert","year":"2002","unstructured":"Wernert, N. et al. The Ets 1 transcription factor is upregulated during inflammatory angiogenesis in rheumatoid arthritis. J. Mol. Med. 80, 258\u2013266 (2002).","journal-title":"J. Mol. Med."},{"key":"BFnrrheum2015164_CR52","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000093198","volume":"43","author":"R Forough","year":"2006","unstructured":"Forough, R. et al. Transcription factor Ets-1 regulates fibroblast growth factor-1-mediated angiogenesis in vivo: role of Ets-1 in the regulation of the PI3K\/AKT\/MMP-1 pathway. J. Vasc. Res. 43, 327\u2013337 (2006).","journal-title":"J. Vasc. Res."},{"key":"BFnrrheum2015164_CR53","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cyto.2010.03.006","volume":"51","author":"L Russell","year":"2010","unstructured":"Russell, L. & Garrett-Sinha, L. A. Transcription factor Ets-1 in cytokine and chemokine gene regulation. Cytokine 51, 217\u2013226 (2010).","journal-title":"Cytokine"},{"key":"BFnrrheum2015164_CR54","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.4049\/jimmunol.177.4.2651","volume":"177","author":"SM Stamatovic","year":"2006","unstructured":"Stamatovic, S. M., Keep, R. F., Mostarica-Stojkovic, M. & Andjelkovic, A. V. CCL2 regulates angiogenesis via activation of Ets-1 transcription factor. J. Immunol. 177, 2651\u20132661 (2006).","journal-title":"J. Immunol."},{"key":"BFnrrheum2015164_CR55","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","volume":"129","author":"BD Manning","year":"2007","unstructured":"Manning, B. D. & Cantley, L. C. AKT\/PKB signaling: navigating downstream. Cell 129, 1261\u20131274 (2007).","journal-title":"Cell"},{"key":"BFnrrheum2015164_CR56","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s11010-012-1463-z","volume":"372","author":"GQ Li","year":"2012","unstructured":"Li, G. Q. et al. PI3 kinase\/Akt\/HIF-1\u03b1 pathway is associated with hypoxia-induced epithelial-mesenchymal transition in fibroblast-like synoviocytes of rheumatoid arthritis. Mol. Cell. Biochem. 372, 221\u2013231 (2012).","journal-title":"Mol. Cell. Biochem."},{"key":"BFnrrheum2015164_CR57","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1182\/blood-2002-04-1237","volume":"101","author":"P Kumar","year":"2003","unstructured":"Kumar, P., Amin, M. A., Harlow, L. A., Polverini, P. J. & Koch, A. E. Src and phosphatidylinositol 3-kinase mediate soluble E-selectin-induced angiogenesis. Blood 101, 3960\u20133968 (2003).","journal-title":"Blood"},{"key":"BFnrrheum2015164_CR58","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1136\/ard.2009.127241","volume":"69","author":"MA Amin","year":"2010","unstructured":"Amin, M. A. et al. Interleukin 18 induces angiogenesis in vitro and in vivo via Src and JNK kinases. Ann. Rheum. Dis. 69, 2204\u20132212 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2015164_CR59","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1002\/1529-0131(200107)44:7<1555::AID-ART279>3.0.CO;2-M","volume":"44","author":"HG Zhang","year":"2001","unstructured":"Zhang, H. G. et al. Regulation of tumor necrosis factor \u03b1-mediated apoptosis of rheumatoid arthritis synovial fibroblasts by the protein kinase Akt. Arthritis Rheum. 44, 1555\u20131567 (2001).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2015164_CR60","doi-asserted-by":"publisher","first-page":"e20454","DOI":"10.1371\/journal.pone.0020454","volume":"6","author":"W Yu","year":"2011","unstructured":"Yu, W. et al. NKX2\u20133 transcriptional regulation of endothelin-1 and VEGF signaling in human intestinal microvascular endothelial cells. PLoS ONE 6, e20454 (2011).","journal-title":"PLoS ONE"},{"key":"BFnrrheum2015164_CR61","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.4049\/jimmunol.0903660","volume":"185","author":"J Liu","year":"2010","unstructured":"Liu, J. & Agarwal, S. Mechanical signals activate vascular endothelial growth factor receptor-2 to upregulate endothelial cell proliferation during inflammation. J. Immunol. 185, 1215\u20131221 (2010).","journal-title":"J. Immunol."},{"key":"BFnrrheum2015164_CR62","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.immuni.2008.03.002","volume":"28","author":"JJ O'Shea","year":"2008","unstructured":"O'Shea, J. J. & Murray, P. J. Cytokine signaling modules in inflammatory responses. Immunity 28, 477\u2013487 (2008).","journal-title":"Immunity"},{"key":"BFnrrheum2015164_CR63","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1136\/ard.2005.050385","volume":"65","author":"JG Walker","year":"2006","unstructured":"Walker, J. G. et al. Changes in synovial tissue JAK-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. Ann. Rheum. Dis. 65, 1558\u20131564 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2015164_CR64","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/ard.2005.037929","volume":"65","author":"JG Walker","year":"2006","unstructured":"Walker, J. G. et al. Expression of JAK3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique JAK3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann. Rheum. Dis. 65, 149\u2013156 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2015164_CR65","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1002\/art.11096","volume":"48","author":"TC van der Pouw Kraan","year":"2003","unstructured":"van der Pouw Kraan, T. C. et al. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum. 48, 2132\u20132145 (2003).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2015164_CR66","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1084\/jem.181.3.1015","volume":"181","author":"TK Sengupta","year":"1995","unstructured":"Sengupta, T. K., Chen, A., Zhong, Z., Darnell, J. E. Jr & Ivashkiv, L. B. Activation of monocyte effector genes and STAT family transcription factors by inflammatory synovial fluid is independent of interferon \u03b3. J. Exp. Med. 181, 1015\u20131025 (1995).","journal-title":"J. Exp. Med."},{"key":"BFnrrheum2015164_CR67","first-page":"1952","volume":"28","author":"A Yokota","year":"2001","unstructured":"Yokota, A. et al. Preferential and persistent activation of the STAT1 pathway in rheumatoid synovial fluid cells. J. Rheumatol. 28, 1952\u20131959 (2001).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum2015164_CR68","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1002\/ibd.22842","volume":"18","author":"K Fang","year":"2012","unstructured":"Fang, K., Zhang, S., Glawe, J., Grisham, M. B. & Kevil, C. G. Temporal genome expression profile analysis during T-cell-mediated colitis: identification of novel targets and pathways. Inflamm. Bowel. Dis. 18, 1411\u20131423 (2012).","journal-title":"Inflamm. Bowel. Dis."},{"key":"BFnrrheum2015164_CR69","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1096\/fj.01-0633fje","volume":"16","author":"D Valdembri","year":"2002","unstructured":"Valdembri, D., Serini, G., Vacca, A., Ribatti, D. & Bussolino, F. In vivo activation of JAK2\/STAT-3 pathway during angiogenesis induced by GM-CSF. FASEB J. 16, 225\u2013227 (2002).","journal-title":"FASEB J."},{"key":"BFnrrheum2015164_CR70","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.mvr.2011.09.011","volume":"83","author":"GA Infusino","year":"2012","unstructured":"Infusino, G. A. & Jacobson, J. R. Endothelial FAK as a therapeutic target in disease. Microvasc. Res. 83, 89\u201396 (2012).","journal-title":"Microvasc. Res."},{"key":"BFnrrheum2015164_CR71","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/nrc3792","volume":"14","author":"FJ Sulzmaier","year":"2014","unstructured":"Sulzmaier, F. J., Jean, C. & Schlaepfer, D. D. FAK in cancer: mechanistic findings and clinical applications. Nat. Rev. Cancer 14, 598\u2013610 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrrheum2015164_CR72","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/emmm.201000106","volume":"2","author":"B Tavora","year":"2010","unstructured":"Tavora, B. et al. Endothelial FAK is required for tumour angiogenesis. EMBO Mol. Med. 2, 516\u2013528 (2010).","journal-title":"EMBO Mol. Med."},{"key":"BFnrrheum2015164_CR73","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0092-8674(00)80664-9","volume":"100","author":"J Schlessinger","year":"2000","unstructured":"Schlessinger, J. New roles for Src kinases in control of cell survival and angiogenesis. Cell 100, 293\u2013296 (2000).","journal-title":"Cell"},{"key":"BFnrrheum2015164_CR74","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1007\/s11033-010-0545-9","volume":"38","author":"PF Hu","year":"2011","unstructured":"Hu, P. F., Chen, Y., Cai, P. F., Jiang, L. F. & Wu, L. D. Sphingosine-1-phosphate: a potential therapeutic target for rheumatoid arthritis. Mol. Biol. Rep. 38, 4225\u20134230 (2011).","journal-title":"Mol. Biol. Rep."},{"key":"BFnrrheum2015164_CR75","doi-asserted-by":"publisher","first-page":"8010","DOI":"10.4049\/jimmunol.181.11.8010","volume":"181","author":"WQ Lai","year":"2008","unstructured":"Lai, W. Q. et al. Anti-inflammatory effects of sphingosine kinase modulation in inflammatory arthritis. J. Immunol. 181, 8010\u20138017 (2008).","journal-title":"J. Immunol."},{"key":"BFnrrheum2015164_CR76","first-page":"424","volume":"14","author":"V Limaye","year":"2009","unstructured":"Limaye, V. et al. Chronic increases in sphingosine kinase-1 activity induce a pro-inflammatory, pro-angiogenic phenotype in endothelial cells. Cell Mol. Biol. Lett. 14, 424\u2013441 (2009).","journal-title":"Cell Mol. Biol. Lett."},{"key":"BFnrrheum2015164_CR77","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/art.21668","volume":"54","author":"M Kitano","year":"2006","unstructured":"Kitano, M. et al. Sphingosine 1-phosphate\/sphingosine 1-phosphate receptor 1 signaling in rheumatoid synovium: regulation of synovial proliferation and inflammatory gene expression. Arthritis Rheum. 54, 742\u2013753 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2015164_CR78","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.4049\/jimmunol.180.3.1921","volume":"180","author":"M Sekiguchi","year":"2008","unstructured":"Sekiguchi, M. et al. Role of sphingosine 1-phosphate in the pathogenesis of Sj\u00f6gren's syndrome. J. Immunol. 180, 1921\u20131928 (2008).","journal-title":"J. Immunol."},{"key":"BFnrrheum2015164_CR79","doi-asserted-by":"publisher","first-page":"6416","DOI":"10.1038\/ncomms7416","volume":"6","author":"C Nussbaum","year":"2015","unstructured":"Nussbaum, C. et al. Sphingosine-1-phosphate receptor 3 promotes leukocyte rolling by mobilizing endothelial P-selectin. Nat. Commun. 6, 6416 (2015).","journal-title":"Nat. Commun."},{"key":"BFnrrheum2015164_CR80","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1756-185X.2012.01756.x","volume":"15","author":"K Masuko","year":"2012","unstructured":"Masuko, K. et al. Sphingosine-1-phosphate modulates expression of vascular endothelial growth factor in human articular chondrocytes: a possible new role in arthritis. Int. J. Rheum. Dis. 15, 366\u2013373 (2012).","journal-title":"Int. J. Rheum. Dis."},{"key":"BFnrrheum2015164_CR81","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/annrheumdis-2012-201978","volume":"72","author":"W Gao","year":"2012","unstructured":"Gao, W. et al. Notch signalling pathways mediate synovial angiogenesis in response to vascular endothelial growth factor and angiopoietin 2. Ann. Rheum. Dis. 72, 1080\u20131088 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2015164_CR82","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1002\/art.34397","volume":"64","author":"W Gao","year":"2012","unstructured":"Gao, W. et al. Notch-1 mediates hypoxia-induced angiogenesis in rheumatoid arthritis. Arthritis Rheum. 64, 2104\u20132113 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2015164_CR83","doi-asserted-by":"publisher","first-page":"e113830","DOI":"10.1371\/journal.pone.0113830","volume":"9","author":"Y Dong","year":"2014","unstructured":"Dong, Y. et al. Oridonin inhibits tumor growth and metastasis through anti-angiogenesis by blocking the Notch signaling. PLoS ONE 9, e113830 (2014).","journal-title":"PLoS ONE"},{"key":"BFnrrheum2015164_CR84","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1161\/01.ATV.0000060892.81529.8F","volume":"23","author":"T Iso","year":"2003","unstructured":"Iso, T., Hamamori, Y. & Kedes, L. Notch signaling in vascular development. Arterioscler. Thromb. Vasc. Biol. 23, 543\u2013553 (2003).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrrheum2015164_CR85","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00595-013-0566-9","volume":"44","author":"H Tamai","year":"2013","unstructured":"Tamai, H. et al. Possible involvement of Notch signaling in the pathogenesis of Buerger's disease. Surg. Today 44, 307\u2013313 (2013).","journal-title":"Surg. Today"},{"key":"BFnrrheum2015164_CR86","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3109\/14397595.2013.844295","volume":"24","author":"K Furuya","year":"2014","unstructured":"Furuya, K., Kaku, Y., Yoshida, K., Joh, K. & Kurosaka, D. Therapeutic effects of sunitinib, one of the anti-angiogenetic drugs, in a murine arthritis. Mod. Rheumatol. 24, 487\u2013491 (2014).","journal-title":"Mod. Rheumatol."},{"key":"BFnrrheum2015164_CR87","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.tranon.2014.09.007","volume":"7","author":"H Li","year":"2014","unstructured":"Li, H. et al. Pazopanib, a receptor tyrosine kinase inhibitor, suppresses tumor growth through angiogenesis in dedifferentiated liposarcoma xenograft models. Transl. Oncol. 7, 665\u2013671 (2014).","journal-title":"Transl. Oncol."},{"key":"BFnrrheum2015164_CR88","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.ejca.2015.01.005","volume":"51","author":"M Xie","year":"2015","unstructured":"Xie, M., He, C. S., Huang, J. K. & Lin, Q. Z. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial. Eur. J. Cancer 51, 595\u2013603 (2015).","journal-title":"Eur. J. Cancer"},{"key":"BFnrrheum2015164_CR89","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1158\/1535-7163.MCT-14-0431","volume":"14","author":"KL Kendra","year":"2014","unstructured":"Kendra, K. L. et al. A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors. Mol. Cancer Ther. 14, 461\u2013469 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrrheum2015164_CR90","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nrd3073","volume":"9","author":"RM Bukowski","year":"2010","unstructured":"Bukowski, R. M., Yasothan, U. & Kirkpatrick, P. Pazopanib. Nat. Rev. Drug Discov. 9, 17\u201318 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrrheum2015164_CR91","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0022-3565(24)37619-0","volume":"286","author":"RL Panek","year":"1998","unstructured":"Panek, R. L. et al. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase. J. Pharmacol. Exp. Ther. 286, 569\u2013577 (1998).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrrheum2015164_CR92","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1517\/13543776.2011.638285","volume":"21","author":"JH Kwak","year":"2011","unstructured":"Kwak, J. H., Jung, J. K. & Lee, H. Nuclear factor-\u03baB inhibitors; a patent review (2006\u20132010). Expert Opin. Ther. Pat. 21, 1897\u20131910 (2011).","journal-title":"Expert Opin. Ther. Pat."},{"key":"BFnrrheum2015164_CR93","doi-asserted-by":"publisher","first-page":"R86","DOI":"10.1186\/ar1958","volume":"8","author":"SW Tas","year":"2006","unstructured":"Tas, S. W. et al. Local treatment with the selective I\u03baB kinase \u03b2 inhibitor NEMO-binding domain peptide ameliorates synovial inflammation. Arthritis Res. Ther. 8, R86 (2006).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2015164_CR94","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1089\/hum.2006.17.821","volume":"17","author":"SW Tas","year":"2006","unstructured":"Tas, S. W. et al. Amelioration of arthritis by intraarticular dominant negative IKK \u03b2 gene therapy using adeno-associated virus type 5. Hum. Gene Ther. 17, 821\u2013832 (2006).","journal-title":"Hum. Gene Ther."},{"key":"BFnrrheum2015164_CR95","doi-asserted-by":"publisher","first-page":"16556","DOI":"10.1073\/pnas.1218219110","volume":"110","author":"B Sehnert","year":"2013","unstructured":"Sehnert, B. et al. NF-\u03baB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-\u03baB in immune-mediated diseases. Proc. Natl Acad. Sci. USA 110, 16556\u201316561 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrrheum2015164_CR96","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jbspin.2011.03.018","volume":"79","author":"JY Choe","year":"2011","unstructured":"Choe, J. Y., Lee, S. J., Park, S. H. & Kim, S. K. Tacrolimus (FK506) inhibits interleukin-1\u03b2-induced angiopoietin-1, Tie-2 receptor, and vascular endothelial growth factor through down-regulation of JNK and p38 pathway in human rheumatoid fibroblast-like synoviocytes. Joint Bone Spine 79, 137\u2013143 (2011).","journal-title":"Joint Bone Spine"},{"key":"BFnrrheum2015164_CR97","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00210-006-0117-7","volume":"374","author":"M Ohori","year":"2007","unstructured":"Ohori, M., Takeuchi, M., Maruki, R., Nakajima, H. & Miyake, H. FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice. Naunyn Schmiedebergs Arch, Pharmacol, 374, 311\u2013316 (2007).","journal-title":"Naunyn Schmiedebergs Arch, Pharmacol"},{"key":"BFnrrheum2015164_CR98","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1124\/jpet.104.078873","volume":"313","author":"BW Ennis","year":"2005","unstructured":"Ennis, B. W. et al. Inhibition of tumor growth, angiogenesis, and tumor cell proliferation by a small molecule inhibitor of c-Jun N-terminal kinase. J. Pharmacol. Exp. Ther. 313, 325\u2013332 (2005).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrrheum2015164_CR99","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1172\/JCI12466","volume":"108","author":"Z Han","year":"2001","unstructured":"Han, Z. et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin. Invest. 108, 73\u201381 (2001).","journal-title":"J. Clin. Invest."},{"key":"BFnrrheum2015164_CR100","doi-asserted-by":"publisher","first-page":"6743","DOI":"10.1074\/jbc.M112.425553","volume":"288","author":"CM Tate","year":"2013","unstructured":"Tate, C. M. et al. LY2228820 dimesylate, a selective inhibitor of p38 mitogen-activated protein kinase, reduces angiogenic endothelial cord formation in vitro and in vivo. J. Biol. Chem. 288, 6743\u20136753 (2013).","journal-title":"J. Biol. Chem."},{"key":"BFnrrheum2015164_CR101","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1053\/gast.2002.30770","volume":"122","author":"D Hommes","year":"2002","unstructured":"Hommes, D. et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122, 7\u201314 (2002).","journal-title":"Gastroenterology"},{"issue":"Suppl. 1","key":"BFnrrheum2015164_CR102","doi-asserted-by":"publisher","first-page":"i77","DOI":"10.1136\/ard.2009.119479","volume":"69","author":"D Hammaker","year":"2010","unstructured":"Hammaker, D. & Firestein, G. S. \u201cGo upstream, young man\u201d: lessons learned from the p38 saga. Ann. Rheum. Dis. 69 (Suppl. 1), i77\u2013i82 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2015164_CR103","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/art.24266","volume":"60","author":"SB Cohen","year":"2009","unstructured":"Cohen, S. B. et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum. 60, 335\u2013344 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2015164_CR104","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/gut.2009.179994","volume":"59","author":"I Dotan","year":"2010","unstructured":"Dotan, I. et al. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease. Gut 59, 760\u2013766 (2010).","journal-title":"Gut"},{"key":"BFnrrheum2015164_CR105","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1053\/j.seminoncol.2003.08.012","volume":"30","author":"LF Allen","year":"2003","unstructured":"Allen, L. F., Sebolt-Leopold, J. & Meyer, M. B. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin. Oncol. 30, 105\u2013116 (2003).","journal-title":"Semin. Oncol."},{"key":"BFnrrheum2015164_CR106","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1158\/1535-7163.MCT-10-0062","volume":"9","author":"YC Henderson","year":"2010","unstructured":"Henderson, Y. C., Chen, Y., Frederick, M. J., Lai, S. Y. & Clayman, G. L. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol. Cancer Ther. 9, 1968\u20131976 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"BFnrrheum2015164_CR107","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2014.12.019","volume":"136","author":"U Matulonis","year":"2014","unstructured":"Matulonis, U. et al. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol. Oncol. 136, 246\u2013253 (2014).","journal-title":"Gynecol. Oncol."},{"key":"BFnrrheum2015164_CR108","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrd2926","volume":"8","author":"P Liu","year":"2009","unstructured":"Liu, P., Cheng, H., Roberts, T. M. & Zhao, J. J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627\u2013644 (2009).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrrheum2015164_CR109","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0014-2999(96)00864-3","volume":"318","author":"T Oikawa","year":"1996","unstructured":"Oikawa, T. & Shimamura, M. Potent inhibition of angiogenesis by wortmannin, a fungal metabolite. Eur. J. Pharmacol. 318, 93\u201396 (1996).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrrheum2015164_CR110","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1093\/annonc\/mds011","volume":"23","author":"B Markman","year":"2012","unstructured":"Markman, B. et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann. Oncol. 23, 2399\u20132408 (2012).","journal-title":"Ann. Oncol."},{"key":"BFnrrheum2015164_CR111","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.3109\/10428194.2014.974040","volume":"56","author":"KP Papadopoulos","year":"2015","unstructured":"Papadopoulos, K. P. et al. Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase\/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory lymphoma. Leuk. Lymphoma 56, 1763\u20131770 (2015).","journal-title":"Leuk. Lymphoma"},{"key":"BFnrrheum2015164_CR112","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1097\/CAD.0000000000000148","volume":"25","author":"X Xing","year":"2014","unstructured":"Xing, X. et al. PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K\/AKT\/mTOR pathway. Anticancer Drugs 25, 1129\u20131140 (2014).","journal-title":"Anticancer Drugs"},{"key":"BFnrrheum2015164_CR113","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/BOR.0b013e32835fd828","volume":"25","author":"RF van Vollenhoven","year":"2013","unstructured":"van Vollenhoven, R. F. Small molecular compounds in development for rheumatoid arthritis. Curr. Opin. Rheumatol. 25, 391\u2013397 (2013).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum2015164_CR114","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven, R. F. et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367, 508\u2013519 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2015164_CR115","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann, R. et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 367, 495\u2013507 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum2015164_CR116","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester, G. R. et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381, 451\u2013460 (2013).","journal-title":"Lancet"},{"key":"BFnrrheum2015164_CR117","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde, D. et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 65, 559\u2013570 (2013).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2015164_CR118","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","volume":"74","author":"EC Keystone","year":"2015","unstructured":"Keystone, E. C. et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann. Rheum. Dis. 74, 333\u2013340 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2015164_CR119","doi-asserted-by":"publisher","first-page":"6601","DOI":"10.1158\/0008-5472.CAN-11-1217","volume":"71","author":"H Xin","year":"2011","unstructured":"Xin, H. et al. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res. 71, 6601\u20136610 (2011).","journal-title":"Cancer Res."},{"key":"BFnrrheum2015164_CR120","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.molonc.2011.10.004","volume":"5","author":"MA Cabrita","year":"2011","unstructured":"Cabrita, M. A. et al. Focal adhesion kinase inhibitors are potent anti-angiogenic agents. Mol. Oncol. 5, 517\u2013526 (2011).","journal-title":"Mol. Oncol."},{"key":"BFnrrheum2015164_CR121","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.4161\/15384101.2015.941760","volume":"13","author":"E Kurenova","year":"2014","unstructured":"Kurenova, E. et al. A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells. Cell Cycle 13, 2542\u20132553 (2014).","journal-title":"Cell Cycle"},{"key":"BFnrrheum2015164_CR122","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2741\/4236","volume":"19","author":"VM Golubovskaya","year":"2014","unstructured":"Golubovskaya, V. M. Targeting FAK in human cancer: from finding to first clinical trials. Front. Biosci. (Landmark Ed.) 19, 687\u2013706 (2014).","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"BFnrrheum2015164_CR123","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1042\/BJ20141165","volume":"465","author":"J Ozanne","year":"2014","unstructured":"Ozanne, J., Prescott, A. R. & Clark, K. The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases. Biochem. J. 465, 271\u2013279 (2014).","journal-title":"Biochem. J."},{"key":"BFnrrheum2015164_CR124","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/art.33336","volume":"64","author":"A Sidibe","year":"2011","unstructured":"Sidibe, A. et al. Soluble VE-cadherin in rheumatoid arthritis patients correlates with disease activity: evidence for tumor necrosis factor \u03b1-induced VE-cadherin cleavage. Arthritis Rheum. 64, 77\u201387 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2015164_CR125","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/cvr\/cvq060","volume":"87","author":"C Sun","year":"2010","unstructured":"Sun, C. et al. ADAM15 regulates endothelial permeability and neutrophil migration via Src\/ERK1\/2 signalling. Cardiovasc. Res. 87, 348\u2013355 (2010).","journal-title":"Cardiovasc. Res."},{"key":"BFnrrheum2015164_CR126","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s12272-014-0340-6","volume":"37","author":"KO Shin","year":"2014","unstructured":"Shin, K. O. et al. Ginsenoside compound K inhibits angiogenesis via regulation of sphingosine kinase-1 in human umbilical vein endothelial cells. Arch. Pharm. Res. 37, 1183\u20131192 (2014).","journal-title":"Arch. Pharm. Res."},{"key":"BFnrrheum2015164_CR127","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1016\/j.bmcl.2013.06.030","volume":"23","author":"DJ Gustin","year":"2013","unstructured":"Gustin, D. J. et al. Structure guided design of a series of sphingosine kinase (SphK) inhibitors. Bioorg. Med. Chem. Lett. 23, 4608\u20134616 (2013).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFnrrheum2015164_CR128","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2011.35.7806","volume":"29","author":"M Fouladi","year":"2011","unstructured":"Fouladi, M. et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J. Clin. Oncol. 29, 3529\u20133534 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrrheum2015164_CR129","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ygyno.2015.03.005","volume":"137","author":"I Diaz-Padilla","year":"2015","unstructured":"Diaz-Padilla, I. et al. A phase II study of single-agent RO4929097, a \u03b3-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: a study of the Princess Margaret, Chicago and California phase II consortia. Gynecol. Oncol. 137, 216\u2013222 (2015).","journal-title":"Gynecol. Oncol."},{"key":"BFnrrheum2015164_CR130","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1007\/s10637-013-0001-5","volume":"31","author":"I Diaz-Padilla","year":"2013","unstructured":"Diaz-Padilla, I. et al. A phase Ib combination study of RO4929097, a \u03b3-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Invest. New Drugs 31, 1182\u20131191 (2013).","journal-title":"Invest. New Drugs"},{"key":"BFnrrheum2015164_CR131","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.pharmthera.2013.02.003","volume":"139","author":"I Espinoza","year":"2013","unstructured":"Espinoza, I. & Miele, L. Notch inhibitors for cancer treatment. Pharmacol.Ther. 139, 95\u2013110 (2013).","journal-title":"Pharmacol.Ther."},{"key":"BFnrrheum2015164_CR132","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s10637-014-0083-8","volume":"32","author":"A De Jesus-Acosta","year":"2014","unstructured":"De Jesus-Acosta, A. et al. A phase II study of the \u03b3 secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Invest. New Drugs 32, 739\u2013745 (2014).","journal-title":"Invest. New Drugs"},{"key":"BFnrrheum2015164_CR133","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10637-013-9965-4","volume":"32","author":"S Richter","year":"2013","unstructured":"Richter, S. et al. A phase I study of the oral \u03b3 secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078\/CTEP 8575). Invest. New Drugs 32, 243\u2013249 (2013).","journal-title":"Invest. New Drugs"},{"key":"BFnrrheum2015164_CR134","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/onc.2011.265","volume":"31","author":"I Hayashi","year":"2011","unstructured":"Hayashi, I. et al. Neutralization of the \u03b3-secretase activity by monoclonal antibody against extracellular domain of nicastrin. Oncogene 31, 787\u2013798 (2011).","journal-title":"Oncogene"},{"key":"BFnrrheum2015164_CR135","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13075-015-0527-3","volume":"17","author":"AR Noort","year":"2015","unstructured":"Noort, A. R., Tak, P. P. & Tas, S. W. Non-canonical NF-\u03baB signaling in rheumatoid arthritis: Dr Jekyll and Mr Hyde? Arthritis Res. Ther. 17, 15 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum2015164_CR136","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1002\/art.22070","volume":"54","author":"M Weinblatt","year":"2006","unstructured":"Weinblatt, M. et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum. 54, 2807\u20132816 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum2015164_CR137","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1136\/annrheumdis-2013-204820","volume":"73","author":"Z Zhu","year":"2014","unstructured":"Zhu, Z. et al. Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using 68Ga-PRGD2 PET\/CT: a prospective proof-of-concept cohort study. Ann. Rheum. Dis. 73, 1269\u20131272 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum2015164_CR138","unstructured":"US National Library of Medicine. Clinicaltrials.gov [online] , (2015)."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2015.164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2015.164","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2015.164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T13:05:28Z","timestamp":1748696728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2015.164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,3]]},"references-count":138,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["BFnrrheum2015164"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2015.164","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,3]]},"assertion":[{"value":"3 December 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}